Pharmarack: Financial Breakdown
Decoding financial health metrics of Pharmarack
Total Revenue₹45.3 Cr19%Prev. FY
Total Expenses₹165.2 Cr19%Prev. FY
Profit After Tax₹-119.9 Cr-20%Prev. FY
Total Assets₹104.5 Cr99%Prev. FY
Net Profit Margin-264.4%-1%Prev. FY
FAQs on Financials of Pharmarack
No. In FY25, Pharmarack reported a net loss of ₹58.9 Cr, so it was not profitable.
Pharmarack's revenue declined 7.9% year-on-year, from ₹45.3 Cr in FY24 to ₹41.8 Cr in FY25.
Pharmarack's estimated EBITDA for FY25 was ₹-54.2 Cr, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY25, Pharmarack posted revenue of ₹41.8 Cr (down 7.9% YoY) and a net loss of ₹58.9 Cr. Explore the full financials of Pharmarack here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links